“We’re working diligently and have been for over one-and-a-half years now. It has been a Herculean effort to get to this point,” Mr Trizzino said.
The Federal Government wants Novavax to be the third shot in Australia’s vaccine arsenal – alongside AstraZeneca and Pfizer.
Mr Trizzino said Novavax scientists had been spending months developing the vaccine, rather than the six to 10 years they usually take in developing one.
But he said it was on track to be ready some time from October this year to January 2022.
“We’re working closely with all of our colleagues in Australia to make sure we get the regulatory submissions in place,” Mr Trizzino said.
Once it passes clinical trials the Novavax vaccine will be manufactured at several locations in Europe.
The Novavax vaccine has a strong ‘prime dose’ in the initial jab then a second dose to get the body’s immune response to strong, Mr Trizzino said.
Novavax has repeatedly pushed back production forecasts as it struggled to gain the raw materials and equipment needed to make its vaccine.
This content first appear on 9news